Targeting pancreatic cancer with specialized platinum drugs.
Precision medicine for pancreatic cancer. Biomarker-guided drug delivery of platinum to tumors
This study is looking at new cancer drugs made with platinum to help treat pancreatic cancer, and it aims to find out how certain markers in tumors can help these drugs work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioplatinum Technologies, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10919357 on NIH RePORTER |
What this research studies
This research focuses on developing new platinum-based anticancer drugs specifically for pancreatic cancer treatment. It aims to understand how the tumor's extracellular matrix and specific biomarkers can enhance the delivery and effectiveness of these drugs. By identifying patients whose tumors express certain biomarkers, the research seeks to tailor treatments that could overcome drug resistance and improve outcomes. The approach combines advanced drug delivery techniques with biomarker analysis to optimize therapy for pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who have tumors expressing high levels of specific biomarkers related to drug sensitivity.
Not a fit: Patients with pancreatic cancer who do not express the targeted biomarkers or have advanced disease stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using biomarker-guided therapies for cancer treatment, suggesting that this approach could be effective, although the specific application to pancreatic cancer with these platinum drugs is relatively novel.
Where this research is happening
Richmond, United States
- Bioplatinum Technologies, LLC — Richmond, United States (Active)
Researchers
- Principal investigator: Farrell, Nicholas Patrick — Bioplatinum Technologies, LLC
- Study coordinator: Farrell, Nicholas Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.